Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.72 and traded as low as $1.36. Eagle Pharmaceuticals shares last traded at $1.50, with a volume of 1,234 shares.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Eagle Pharmaceuticals in a report on Tuesday. They set a “hold” rating on the stock.

Eagle Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $0.79 and a 200-day simple moving average of $1.72.

Institutional Trading of Eagle Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning acquired a new stake in Eagle Pharmaceuticals in the third quarter valued at $59,000. Jane Street Group LLC acquired a new stake in Eagle Pharmaceuticals in the third quarter valued at $96,000. DGS Capital Management LLC raised its stake in Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after buying an additional 22,239 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Eagle Pharmaceuticals in the third quarter valued at $453,000. Finally, RBF Capital LLC raised its stake in Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after buying an additional 14,991 shares in the last quarter. 85.36% of the stock is currently owned by institutional investors and hedge funds.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.